Pfizer (PFE) Change in Cash (2009 - 2026)

Pfizer (PFE) has 18 years of Change in Cash data on file, last reported at $563.0 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $563.0 million, up 50.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $279.0 million (up 108.76% YoY), and the FY2025 annual result was $91.0 million, up 105.03% from the prior year.
• Change in Cash grew to $563.0 million in Q1 2026 per PFE's latest filing, from -$196.0 million in the prior quarter.
• Over five years, Change in Cash peaked at $1.8 billion in Q2 2023 and troughed at -$2.1 billion in Q1 2024.
• A 5-year average of -$84.1 million and a median of $213.0 million in 2025 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2024: Change in Cash surged 3626.67% in 2022, then sank 429.91% in 2024.
• A 5-year view of Change in Cash shows it stood at -$646.0 million in 2022, then soared by 51.08% to -$316.0 million in 2023, then sank by 458.54% to -$1.8 billion in 2024, then soared by 88.9% to -$196.0 million in 2025, then soared by 387.24% to $563.0 million in 2026.
• Business Quant data shows PFE's Change in Cash at $563.0 million in Q1 2026, -$196.0 million in Q4 2025, and -$301.0 million in Q3 2025.